Compare, Analyse Dishman Pharma with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ACTAVIS (US) - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DISHMAN PHARMA   ACTAVIS
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ACTAVIS
Dec-18
DISHMAN PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs37413,781-   
Low Rs1299,244-   
Sales per share (Unadj.) Rs197.83,380.5-  
Earnings per share (Unadj.) Rs21.2-1,088.9-  
Cash flow per share (Unadj.) Rs34.7356.2-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.913,942.9-  
Shares outstanding (eoy) m80.69332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.4 37.4%   
Avg P/E ratio x11.9-10.6 -112.2%  
P/CF ratio (eoy) x7.232.3 22.4%  
Price / Book Value ratio x1.40.8 169.4%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3063,829,128 0.5%   
No. of employees `0000.816.9 4.9%   
Total wages/salary Rs m5,3550-   
Avg. sales/employee Rs Th19,252.766,529.6 28.9%   
Avg. wages/employee Rs Th6,459.50-   
Avg. net profit/employee Rs Th2,064.1-21,429.2 -9.6%   
INCOME DATA
Net Sales Rs m15,9611,124,350 1.4%  
Other income Rs m26521,501 1.2%   
Total revenues Rs m16,2261,145,851 1.4%   
Gross profit Rs m4,10329,464 13.9%  
Depreciation Rs m1,091480,635 0.2%   
Interest Rs m94464,881 1.5%   
Profit before tax Rs m2,334-494,552 -0.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0126,131 0.0%   
Tax Rs m624-6,267 -9.9%   
Profit after tax Rs m1,711-362,154 -0.5%  
Gross profit margin %25.72.6 981.0%  
Effective tax rate %26.71.3 2,108.7%   
Net profit margin %10.7-32.2 -33.3%  
BALANCE SHEET DATA
Current assets Rs m11,018461,150 2.4%   
Current liabilities Rs m9,517407,948 2.3%   
Net working cap to sales %9.44.7 198.7%  
Current ratio x1.21.1 102.4%  
Inventory Days Days11020 564.2%  
Debtors Days Days3566 52.5%  
Net fixed assets Rs m16,304127,270 12.8%   
Share capital Rs m1610-   
"Free" reserves Rs m12,9070-   
Net worth Rs m14,5164,637,419 0.3%   
Long term debt Rs m4,1891,633,003 0.3%   
Total assets Rs m29,8057,249,341 0.4%  
Interest coverage x3.5-6.6 -52.4%   
Debt to equity ratio x0.30.4 82.0%  
Sales to assets ratio x0.50.2 345.3%   
Return on assets %8.9-4.1 -217.3%  
Return on equity %11.8-7.8 -150.9%  
Return on capital %17.5-4.8 -362.1%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Net fx Rs m4,2550-   
CASH FLOW
From Operations Rs m2,786401,688 0.7%  
From Investments Rs m-1,529220,675 -0.7%  
From Financial Activity Rs m-941-689,417 0.1%  
Net Cashflow Rs m316-66,719 -0.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 71.22 Rs / USD

Compare DISHMAN PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare DISHMAN PHARMA With: STERLING BIOTECH  SUVEN LIFESCIENCES  PANACEA BIOTECH  VENUS REMEDIES  AUROBINDO PHARMA  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views On News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound (Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound? (The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival (Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market (The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound (The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS